Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

"Dosing the first patient in the TNG456 Phase I/II trial marks a significant step for us and for patients with MTAP-deleted GBM," Adam Crystal, Tango's president of R&D, said in a statement. "People ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.

NEW YORK – Cizzle Biotechnology said on Tuesday it has raised £150,000 ($200,635) to support the rollout of its lung cancer early detection test in the UK and other European countries.

Healthcare Royalty Partners purchased anticipated royalties and milestone payments, and Regenxbio received $150 upfront at closing.

NEW YORK – CRISPR Therapeutics and Sirius Therapeutics have inked a deal valued at up to $95 million to develop and commercialize small interfering RNA therapies, starting with a treatment for ...

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Moving forward, the biotech said it will focus its resources on developing treatments for genetic liver diseases and on its partnered programs.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The ASO for myotonic dystrophy type 1 was well tolerated and improved splicing and function in a study presented at ASGCT.